Dauntless Investment Group LLC Purchases Shares of 96,208 Cardiff Oncology, Inc. (NASDAQ:CRDF)

Key Points

• Dauntless Investment Group LLC has purchased 96,208 shares of Cardiff Oncology, Inc. valued at approximately $302,000, indicating growing institutional interest in the company.
• Cardiff Oncology's stock currently has a market cap of $248.14 million, with a price target of $18.00 set by HC Wainwright, reflecting positive analyst sentiment.
• The company recently reported a quarterly loss of ($0.20) earnings per share, missing analyst expectations but showing revenue slightly above predictions.

Dauntless Investment Group LLC purchased a new stake in Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 96,208 shares of the company's stock, valued at approximately $302,000. Dauntless Investment Group LLC owned approximately 0.14% of Cardiff Oncology at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets acquired a new stake in Cardiff Oncology in the fourth quarter valued at $25,000. Thoroughbred Financial Services LLC raised its holdings in shares of Cardiff Oncology by 43.8% during the fourth quarter. Thoroughbred Financial Services LLC now owns 19,614 shares of the company's stock worth $85,000 after purchasing an additional 5,970 shares during the period. American Century Companies Inc. raised its holdings in shares of Cardiff Oncology by 12.8% during the fourth quarter. American Century Companies Inc. now owns 53,955 shares of the company's stock worth $234,000 after purchasing an additional 6,140 shares during the period. Wells Fargo & Company MN raised its holdings in shares of Cardiff Oncology by 38.1% during the fourth quarter. Wells Fargo & Company MN now owns 32,064 shares of the company's stock worth $139,000 after purchasing an additional 8,851 shares during the period. Finally, Barclays PLC raised its holdings in shares of Cardiff Oncology by 17.9% during the fourth quarter. Barclays PLC now owns 62,596 shares of the company's stock worth $272,000 after purchasing an additional 9,507 shares during the period. 16.29% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on CRDF. HC Wainwright increased their target price on shares of Cardiff Oncology from $17.00 to $18.00 and gave the stock a "buy" rating in a report on Friday, May 9th. Jefferies Financial Group began coverage on shares of Cardiff Oncology in a report on Tuesday, June 24th. They set a "hold" rating and a $3.50 target price on the stock. William Blair reissued an "outperform" rating on shares of Cardiff Oncology in a report on Wednesday, June 18th. Finally, LADENBURG THALM/SH SH began coverage on shares of Cardiff Oncology in a report on Tuesday, July 8th. They set a "buy" rating and a $19.00 target price on the stock. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, Cardiff Oncology presently has a consensus rating of "Moderate Buy" and an average target price of $11.70.

Cardiff Oncology Stock Performance

Shares of Cardiff Oncology stock traded up $0.34 during trading on Friday, hitting $2.71. 4,966,455 shares of the stock were exchanged, compared to its average volume of 1,429,650. The stock's fifty day moving average is $3.60 and its 200 day moving average is $3.50. The stock has a market cap of $180.42 million, a PE ratio of -3.12 and a beta of 1.52. Cardiff Oncology, Inc. has a 12 month low of $2.01 and a 12 month high of $5.64.

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.02). The firm had revenue of $0.12 million for the quarter, compared to the consensus estimate of $0.11 million. Cardiff Oncology had a negative return on equity of 77.94% and a negative net margin of 9,344.14%. Sell-side analysts anticipate that Cardiff Oncology, Inc. will post -0.99 EPS for the current fiscal year.

Insider Transactions at Cardiff Oncology

In related news, Director Gary W. Pace bought 275,000 shares of the firm's stock in a transaction that occurred on Wednesday, July 30th. The stock was purchased at an average price of $2.45 per share, for a total transaction of $673,750.00. Following the transaction, the director directly owned 1,330,676 shares of the company's stock, valued at approximately $3,260,156.20. This represents a 26.05% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 7.70% of the stock is owned by corporate insiders.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.